Show simple item record

dc.contributor.authorDriuchina, Anastasiia
dc.contributor.authorHintikka, Jukka
dc.contributor.authorLehtonen, Marko
dc.contributor.authorKeski-Rahkonen, Pekka
dc.contributor.authorO’Connell, Thomas
dc.contributor.authorJuvonen, Risto
dc.contributor.authorKuula, Juho
dc.contributor.authorHakkarainen, Antti
dc.contributor.authorLaukkanen, Jari A.
dc.contributor.authorMäkinen, Elina
dc.contributor.authorLensu, Sanna
dc.contributor.authorPietiläinen, Kirsi H.
dc.contributor.authorPekkala, Satu
dc.date.accessioned2023-02-07T07:37:09Z
dc.date.available2023-02-07T07:37:09Z
dc.date.issued2023
dc.identifier.citationDriuchina, A., Hintikka, J., Lehtonen, M., Keski-Rahkonen, P., O’Connell, T., Juvonen, R., Kuula, J., Hakkarainen, A., Laukkanen, J. A., Mäkinen, E., Lensu, S., Pietiläinen, K. H., & Pekkala, S. (2023). Identification of Gut Microbial Lysine and Histidine Degradation and CYP-Dependent Metabolites as Biomarkers of Fatty Liver Disease. <i>mBio</i>, <i>14</i>(1), Article e02663-22. <a href="https://doi.org/10.1128/mbio.02663-22" target="_blank">https://doi.org/10.1128/mbio.02663-22</a>
dc.identifier.otherCONVID_176631959
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/85374
dc.description.abstractNumerous studies have described specific metabolites as biomarkers ofsevere liver diseases, but very few have measured gut microbiota (GM)-produced metab-olites in fatty liver disease. We aimed atfinding GM signatures and metabolite markersin plasma and feces related to high liver fat content. Based on imaging, we dividedstudy participants into low (,5%, LF,n= 25) and high (.5%, HF,n= 39) liver fatgroups. Fecal (LFn= 14, HFn= 25) and plasma (LFn= 11, HFn= 7) metabolomes ofsubsets of participants were studied using liquid chromatography/high resolution massspectrometry. The GM were analyzed using 16S rRNA gene sequencing. Additionally,blood clinical variables and diet were studied. Dyslipidemia, higher liver enzymes and in-sulin resistance characterized the HF group. No major differences in diet were foundbetween the groups. In the GM, the HF group had lower abundance ofBacteroidesandPrevotellaceae NK3B31 group than the LF group after adjusting for metformin use orobesity. In feces, the HF group had higher levels of lysine and histidine degradationproducts, while 6-hydroxybetatestosterone (metabolized by CYP3A4) was low. Higherplasma levels of caffeine and its metabolites in the HF group indicate that the activity ofhepatic CYP1A2 was lower than in the LF group. Our results suggest, that low fecalPrevotellaceae NK3B31 andBacteroidesabundance, and increased lysine and histidinedegradation may serve as GM biomarkers of high liver fat. Altered plasma caffeinemetabolites and lowered testosterone metabolism may specify decreased CYP activities,and their potential utility, as biomarkers of fatty liver disease.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.relation.ispartofseriesmBio
dc.rightsCC BY 4.0
dc.subject.othergut microbiota
dc.subject.otherinsulin resistance
dc.subject.otherliver fat
dc.subject.othermetabolomics
dc.titleIdentification of Gut Microbial Lysine and Histidine Degradation and CYP-Dependent Metabolites as Biomarkers of Fatty Liver Disease
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202302071654
dc.contributor.laitosPsykologian laitosfi
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosDepartment of Psychologyen
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineLiikuntalääketiedefi
dc.contributor.oppiaineLiikuntafysiologiafi
dc.contributor.oppiaineHyvinvoinnin tutkimuksen yhteisöfi
dc.contributor.oppiaineKäyttäytymisen muutos, hyvinvointi ja terveys elämänkulussafi
dc.contributor.oppiaineSports and Exercise Medicineen
dc.contributor.oppiaineExercise Physiologyen
dc.contributor.oppiaineSchool of Wellbeingen
dc.contributor.oppiaineBehaviour change, health, and well-being across the lifespanen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn2161-2129
dc.relation.numberinseries1
dc.relation.volume14
dc.type.versionpublishedVersion
dc.rights.copyright© 2023 Driuchina et al.
dc.rights.accesslevelopenAccessfi
dc.relation.grantnumber316966
dc.relation.grantnumber321522
dc.relation.grantnumber308042
dc.relation.grantnumber349264
dc.subject.ysorasvamaksa
dc.subject.ysoaineenvaihduntahäiriöt
dc.subject.ysoinsuliiniresistenssi
dc.subject.ysosuolistomikrobisto
dc.subject.ysomaksa
dc.subject.ysoinsuliini
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p21481
jyx.subject.urihttp://www.yso.fi/onto/yso/p6239
jyx.subject.urihttp://www.yso.fi/onto/yso/p22290
jyx.subject.urihttp://www.yso.fi/onto/yso/p37925
jyx.subject.urihttp://www.yso.fi/onto/yso/p11264
jyx.subject.urihttp://www.yso.fi/onto/yso/p8422
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1128/mbio.02663-22
dc.relation.funderResearch Council of Finlanden
dc.relation.funderResearch Council of Finlanden
dc.relation.funderResearch Council of Finlanden
dc.relation.funderResearch Council of Finlanden
dc.relation.funderSuomen Akatemiafi
dc.relation.funderSuomen Akatemiafi
dc.relation.funderSuomen Akatemiafi
dc.relation.funderSuomen Akatemiafi
jyx.fundingprogramAcademy Project, AoFen
jyx.fundingprogramAcademy Project, AoFen
jyx.fundingprogramAcademy Research Fellow, AoFen
jyx.fundingprogramAcademy Project, AoFen
jyx.fundingprogramAkatemiahanke, SAfi
jyx.fundingprogramAkatemiahanke, SAfi
jyx.fundingprogramAkatemiatutkija, SAfi
jyx.fundingprogramAkatemiahanke, SAfi
jyx.fundinginformationSatu Pekkala was funded by the Academy of Finland (grant numbers 308042 and 349264), and by the ERVA funding of the Southwest Finland Health Care District. The study was also supported by the Academy of Finland funded Profiling of University of Jyväskylä and the Faculty of Sport and Health Sciences: Physical activity through life span (PACTS2). Kirsi H. Pietiläinen was funded by the Academy of Finland (grant numbers 335443, 314383, 272376, 266286), Finnish Medical Foundation, Gyllenberg Foundation, Novo Nordisk Foundation (grant numbers NNF20OC0060547, NNF17OC0027232, NNF10OC1013354), Finnish Diabetes Research Foundation, University of Helsinki, and Helsinki University Hospital Government Research Funds. Sanna Lensu was funded from the projects by the Academy of Finland (grant ID 316966 and 321522), and grants from Jenny & Artturi Wihuri Foundation and the Central Finland Regional Fund of the Finnish Cultural Foundation.
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0